Kymera Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, orally available small-molecule drugs targeting the ubiquitin system for the treatment of cancer and other diseases. Kymera’s proprietary technology platform enables the design of novel molecules that potently and selectively modulate key proteins in the ubiquitin system.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel, first-in-class therapeutics to modulate cytokines. The Company’s lead product candidate, KT-155, is a small molecule inhibitor of interleukin (IL)-15 that is being developed for the treatment of autoimmune diseases and cancer.
Kymera Therapeutics Ipo
Kymera Therapeutics, a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a price to the public of $16.00 per share. Kymera’s common stock is expected to begin trading on The Nasdaq Global Market on October 5, 2018, under the ticker symbol “KYMR.” Goldman Sachs & Co.
LLC and J.P. Morgan are acting as joint book-running managers for the offering. Cowen and Company, LLC is acting as the lead manager for the offering. Guggenheim Securities LLC is acting as co-manager for the offering.
The gross proceeds from this offering are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Kymera.
Credit: bostonrealestatetimes.com
What Does Kymera Therapeutics Do?
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing novel, first-in-class therapeutics that modulate the ubiquitin system. The company’s lead program is in development for the treatment of autoimmune diseases and cancer. Kymera’s proprietary platform leverages its deep understanding of how to selectively target proteins for degradation by the ubiquitin system.
How Many Employees Does Kymera Therapeutics Have?
Kymera Therapeutics, a clinical-stage biopharmaceutical company, has approximately 50 employees. The company is focused on the discovery and development of next-generation small molecule therapeutics for the treatment of cancer and other serious diseases. Kymera’s proprietary platform enables the rapid and efficient generation of highly potent and selective compounds that target disease-causing proteins.
Kymera’s lead product candidate, KYM-001, is a first-in-class, orally available small molecule inhibitor of SHP2 (src homology 2 domain-containing protein tyrosine phosphatase 2), which is a key regulator of signaling pathways that drive cancer cell proliferation, survival and metastasis. KYM-001 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
Who Founded Kymera?
Kymera was founded in 2006 by a team of experienced entrepreneurs and engineers. The company’s mission is to provide customers with innovative, reliable, and easy-to-use products that improve their quality of life. Kymera’s first product, the Kymera Body Wand, was developed to help people who suffer from chronic pain and stiffness.
The Body Wand is a portable, battery-operated device that uses low-level electrical stimulation to relieve pain.
Is Kymera a Public Company?
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, first-in-class medicines to treat cancer and other serious diseases. Kymera is a privately held company headquartered in Cambridge, Massachusetts.
Conclusion
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, orally available small-molecule drugs targeting the ubiquitin system for the treatment of cancer and other diseases. Kymera’s lead drug candidate, KYM-001, is in a Phase 1/2 clinical trial in patients with relapsed or refractory solid tumors. Kymera is headquartered in Cambridge, MA.
